



Signaling Pathways and Immune-Checkpoint Regulation in Cancers

Guest Editor:

Dr. Silvia Vivarelli

Department of Biomedical and Dental Sciences and Morphofunctional Imaging (BIOMORF), Occupational Medicine Section, University of Messina, Messina, Italy

Deadline for manuscript submissions:
closed (15 June 2023)

Message from the Guest Editor

Dear Colleagues,

Seeking better knowledge of signaling pathways involved in immune-checkpoint regulation might help to overcome arising issues and improve the overall benefits of this revolutionary interventional approach. For example, the latest milestone research has revealed how interindividual variations in intestinal microbiome may play a pivotal role in the observed heterogeneity of the response to immune-checkpoint inhibitors.

This Special Issue, entitled “Signaling Pathways and Immune-Checkpoint Regulation in Cancers”, welcomes contributions in the form of original research articles or reviews, aiming to shed light and explore all the novel molecular players involved in the inhibition of both known (e.g., CTLA-4, PD-1/PD-L1) and emerging (e.g., CD47, TIGIT, KIR-L, LAG-3, TIM-3, etc.) immune checkpoints.

Dr. Silvia Vivarelli
Guest Editor





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and
Center for Clinical Research
Learning, Spaulding
Rehabilitation Hospital and
Massachusetts General Hospital,
Harvard Medical School, Boston,
MA 02114, USA
2. Department of Epidemiology,
Harvard T.H. Chan School of
Public Health, Boston, MA 02115,
USA

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within *Scopus*, *SCIE (Web of Science)*, *PubMed*, *PMC*, *CAPus / SciFinder*, and other databases.

Journal Rank: JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q2 (*Medicine (miscellaneous)*)

Contact Us

Biomedicines Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/biomedicines
biomedicines@mdpi.com
X@Biomed_MDPI